Clinical Nurse Specialist Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Wade Anderson

Clinical Nurse Specialist, Family Health Gunnison, UT Clinical Nurse Specialist

NPI 1578749123 CMS profile 11209035

85 N 100 E, Suite A, Gunnison, UT 84634

Open in the dashboard

General payments

$297

17 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Wade Anderson of Gunnison, UT is reported in the CMS Open Payments database as having received $297 across 17 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 46th percentile of Clinical Nurse Specialist, Family Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $62 3
2024 General $44 3
2023 General $51 3
2022 General $48 3
2021 General $92 5

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Wade Anderson
  • Clinical Nurse Specialist, Family Health median
  • Middle half of Clinical Nurse Specialist, Family Health
  • National median

In program year 2025, general payments to Wade Anderson were reported at $62. Among 164 Clinical Nurse Specialist, Family Health profiles paid that year, the median was $216 and the middle half received between $57 and $492.

Show as a table
Year Wade Anderson Clinical Nurse Specialist, Family Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $92 $151 $46–$400 $132
2022 $48 $153 $37–$527 $149
2023 $51 $139 $50–$451 $160
2024 $44 $150 $46–$571 $164
2025 $62 $216 $57–$492 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $133 7 payments
  2. Pfizer Inc. $40 2 payments
  3. Sanofi Pasteur Inc. $18 1 payment
  4. Merck Sharp & Dohme Corporation $17 1 payment
  5. GlaxoSmithKline, LLC. $16 1 payment
  6. Neurelis, Inc. $15 1 payment
  7. Idorsia Pharmaceuticals US Inc $14 1 payment
  8. Boston Scientific Corporation $14 1 payment
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $14 1 payment
  10. Novo Nordisk Inc $14 1 payment

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $297 17 payments
Products named General payments · program years 2021–2025
  1. VRAYLAR Neuroscience $90 5 payments
  2. COLOGUARD DNA CAPTURE REAGENTS $40 2 payments
  3. PREMARIN $36 2 payments
  4. REYVOW $22 1 payment
  5. VRAYLAR Neuroscience $22 1 payment
  6. UBRELVY $21 1 payment
  7. QULIPTA $21 1 payment
  8. FLUZONE QUADRIVALENT NORTHERN HEMISPHERE $18 1 payment
  9. BEYFORTUS $18 1 payment
  10. VERQUVO $17 1 payment
  11. Other $119 8 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 151 drugs

Part D claims

9,706

Median for Physician Assistant: 241

Drug cost

$434,944

Median for Physician Assistant: $4,110

Branded share of claims

17.9%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 146 $102,170
Mounjaro Tirzepatide Brand 47 $50,427
Ozempic Semaglutide Brand 47 $44,365
Tradjenta Linagliptin Brand 23 $11,887
Myrbetriq Mirabegron Brand 13 $11,527
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 18 $11,441
Toujeo Solostar Insulin Glargine,hum.Rec.Anlog Brand 14 $11,211
Jardiance Empagliflozin Brand 11 $11,169
Toujeo Max Solostar Insulin Glargine,hum.Rec.Anlog Brand 15 $7,942
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 211 $7,284

The 10 drugs with the highest cost, of 151 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 78 billing codes

Paid by Medicare

$66,611

Of which drugs: $5,877

Medicare patients

255

Average age 75

Services billed

3,266

140 women, 115 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 47%
Arthritis 40%
Diabetes 30%
Ischemic heart disease 17%
Chronic kidney disease 12%
Depression 12%
Heart failure 11%
Atrial fibrillation 11%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 12 12 $3,019
Vaccine for influenza for injection into muscle 90662 Office 28 28 $2,281
Injection, methylprednisolone acetate, 1 mg J1010 Office 12 1,000 $70
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 18 47 $39
Injection, ceftriaxone sodium, per 250 mg J0696 Office 21 129 $36
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 11 44 $22

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BEXSERO
  • GlaxoSmithKline, LLC. $16
$16 — —
VRAYLAR
  • AbbVie, Inc. $13
$13 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

17 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Nurse Specialist, Family Health in Utah

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record